Jaime Rosenberg

Emerging therapies for psoriasis and psoriatic arthritis (PsA) include treatments that target interleukin (IL)-23 and IL-17, which could lead to the approval of new IL-23 and IL-17 inhibitors, as well as expanding the use of currently approved options.

The program, serving patients from rheumatology, dermatology, gastroenterology, allergy, and cardiology clinics, is the first of its kind within the Veterans Health Administration, researchers said.

The findings follow recent data suggesting that esophageal dysmotility may be associated with eosinophilic esophagitis (EoE), which often presents with dysphagia.

The study, say researchers, adds insight into risk factors predictive of response to dietary intervention for eosinophilic esophagitis (EoE), as dietary failure occurs in up to 30% of patients.

Highlighting their ability to quickly destroy malignant cells without antigen specificity, natural killer (NK) cells have been identified as an opportunity for use, particularly in cases where T cells are not effective.

In a proof-of-concept analysis, researchers show that machine learning methods paired with longitudinal patient-reported outcomes (PRO) data were able to classify subsequent rheumatoid arthritis (RA) disease activity after beginning treatment with a biologic

Data suggest that the technology may be an option for patients who are ineligible for autologous stem cell transplantation (ASCT) based on certain patient characteristics, prior treatments, stem cell availability, or tumor chemosensitivity.

While the prevalence of eosinophilic esophagitis (EoE) is estimated to be 0.5% in the general population, a recent study found that the prevalence was as high as 16.5% in patients with allergic disease.

Prior to the analysis, researchers hypothesized that having localized psoriasis on more visible and/or more sensitive areas, including the face and genitals, would yield a more significant impact on quality of life.

Risk of osteoporosis and bone fractures in rheumatoid arthritis (RA) stem from disease-specific causes, disease treatment, and factors that face the general population, according to researchers, who highlighted the importance of assessing risk factors in these patients.

Though typically associated with effects on the joints, rheumatoid arthritis (RA) was found have a pulmonary effect in nearly 3 in 4 patients included in the retrospective, single-center study.

In the last 2 years, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the European Alliance of Associations for Rheumatology (EULAR) have updated their recommendations to integrate guidance for new treatment options.

Researchers highlighted the opportunities primary care providers (PCPs) have to promote favorable outcomes through prompt diagnosis as well as help reduce racial disparities in multiple myeloma.

The study, which assessed changes in circRNA and miRNA after beginning treatment with secukinumab, revealed a prompt change in circRNA abundance upon initiation of treatment and a strong correlation between circRNA and the psoriasis area and severity index.

Based on their findings, the researchers are emphasizing the importance of patients with rheumatoid arthritis (RA) receiving a booster vaccination, as well as other mitigation strategies, such as social distancing and wearing face masks.

The exploration of whether early intervention has an impact in psoriasis follows data from other immune-mediated diseases in which evidence is mounting for the benefits of intervening early on in disease duration.

In the absence of a head-to-head trial, the researchers compiled data from randomized controlled trials of the 2 PD-1/PD-L1 inhibitors in patients with advanced disease and PD-L1 ≥ 50%.

Data showed that patients using diabetes technology incorporated different strategies to prevent nocturnal hypoglycemia vs patients who did not use such technology.

Overall, 65% of patients went into remission throughout the observation period, with those with concurrent eczema and pollen food syndrome (PFS) having favorable responses.

This new series of cases suggests that technology can help nurses remotely identify relevant health events that could be indicative of exacerbations or changes in their condition.

With these new findings coming from the EMPOWER-Lung 3 trial, the anti-programmed cell death-1 inhibitor cemiplimab is now just the second of its kind to show efficacy in these patients as both monotherapy and as a combination regimen, regardless of histology.

The findings, produced over a 4-year period, indicate the protein sulfatase-2 (Sulf-2) may be a therapeutic target in rheumatoid arthritis (RA).

This randomized, multicenter study of children and adolescents with new-onset type 1 diabetes (T1D) investigated the effect on glucose control of a closed-loop system, using C-peptide levels to gauge response

The study analyzed 20 clinical prediction models (CPMs) for rheumatoid arthritis (RA), all of which were deemed to have a high risk of bias, leading the researchers to urge against their use to guide decision-making without addressing their limitations.

The study also found that over a decade, death rates did not change significantly for ankylosing spondylitis but decreased for inflammatory bowel disease (IBD).

Data from a literature review of 41 studies were analyzed and subsequently leveraged to create a survey among physicians on the use of 4 targeted therapies in systemic sclerosis-interstitial lung disease (SSc-ILD).

The review included data from 17 studies of over 400 patients using continuous glucose monitors (CGM).

Problematic nail conditions range from nail psoriasis (NP) to paronychia, which are commonly seen in clinical practice and result from infectious, inflammatory, neoplastic and traumatic etiologies.

The trial followed patients with type 1 diabetes (T1D) for 6 months, evaluating outcomes in patients struggling to achieve glucose targets with the conventional treatment.

This analysis of 5 studies found that, compared with placebo, all biologic regimens improved Psoriasis Area and Severity Index (PASI) 90 response—considered a gold standard goal due to its correlation with quality of life.